Regeneron Pharmaceuticals, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Regeneron Pharmaceuticals, Inc. has submitted its 2023 annual report on Form 10-K, detailing its financial performance and business operations for the fiscal year ending December 31, 2023.</b>

AI Summary

REGENERON PHARMACEUTICALS, INC. (REGN) filed a Annual Report (10-K) with the SEC on February 5, 2024. Regeneron Pharmaceuticals, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. The company's principal executive offices are located at 777 Old Saw Mill River Road, Tarrytown, NY 10591. Regeneron Pharmaceuticals, Inc. is classified under the SIC code 2834 for Pharmaceutical Preparations. The report was filed as of February 5, 2024.

Why It Matters

For investors and stakeholders tracking REGENERON PHARMACEUTICALS, INC., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Regeneron's financial health, operational performance, and strategic direction for the past fiscal year, which is crucial for investors to assess the company's current standing and future prospects. The detailed financial data and risk factors disclosed in the 10-K are essential for stakeholders to make informed investment decisions and understand potential challenges the company may face.

Risk Assessment

Risk Level: low — REGENERON PHARMACEUTICALS, INC. shows low risk based on this filing. The risk is low as this is a standard annual filing providing historical financial data and business overview, with no immediate negative indicators present in the provided snippet.

Analyst Insight

Investors should review the full 10-K filing to understand Regeneron's financial performance, product pipeline, and strategic initiatives for 2023.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-02-05 — Filing Date (Date of submission)
• 139 — Public Document Count (Number of documents in the filing)
• 000-19034 — SEC File Number (SEC registration number)

Key Players & Entities

• REGENERON PHARMACEUTICALS, INC. (company) — Filer name
• REGN (company) — Ticker symbol
• 777 OLD SAW MILL RIVER ROAD (company) — Business address street
• TARRYTOWN (company) — Business address city
• NY (company) — Business address state
• 10591 (company) — Business address zip
• 2834 (company) — Standard Industrial Classification
• Robert E. Landry (person) — Director/Officer

Forward-Looking Statements

• Regeneron will continue to report product revenue as a primary income stream. (REGENERON PHARMACEUTICALS, INC.) — high confidence, target: 2024-12-31

FAQ

Industry Context

Regeneron Pharmaceuticals operates within the pharmaceutical preparations industry, focusing on the discovery, development, and commercialization of medicines.

Regulatory Implications

The company is subject to regulations by the Securities and Exchange Commission (SEC) for its public filings, including this Form 10-K.

What Investors Should Do

1. Analyze the financial statements and management's discussion and analysis within the 10-K.
2. Identify key product revenues and collaboration revenues for the fiscal year 2023.
3. Review any disclosed risk factors that could impact future performance.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-02-05: Filing Date — Date the 10-K was officially submitted to the SEC.

Year-Over-Year Comparison

This is the initial filing snippet provided, so a comparison to a previous filing is not possible.

Key Financial Figures

• $6 million — mber 31, 2023 and 2022 is approximately $6 million and $34 million, respectively, of net p
• $34 m — nd 2022 is approximately $6 million and $34 million, respectively, of net product sal

Filing Documents

• regn-20231231.htm (10-K) — 3250KB
• regn-ex_1036x12312023x10k.htm (EX-10.3 6) — 74KB
• regn-ex_1037x12312023x10k.htm (EX-10.3 7) — 60KB
• regn-ex_211x12312023x10k.htm (EX-21.1) — 19KB
• regn-ex_231x12312023x10k.htm (EX-23.1) — 3KB
• regn-ex_311x12312023x10k.htm (EX-31.1) — 12KB
• regn-ex_312x12312023x10k.htm (EX-31.2) — 12KB
• regn-ex_32x12312023x10k.htm (EX-32) — 7KB
• regn-ex_971x12312023x10k.htm (EX-97.1) — 39KB
• regn-20231231_g1.jpg (GRAPHIC) — 107KB
• 0001804220-24-000009.txt (&nbsp;) — 14836KB
• regn-20231231.xsd (EX-101.SCH) — 96KB
• regn-20231231_cal.xml (EX-101.CAL) — 116KB
• regn-20231231_def.xml (EX-101.DEF) — 553KB
• regn-20231231_lab.xml (EX-101.LAB) — 1069KB
• regn-20231231_pre.xml (EX-101.PRE) — 801KB
• regn-20231231_htm.xml (XML) — 2264KB

Business

Business 2 Item 1A.

Risk Factors

Risk Factors 38 Item 1B. Unresolved Staff Comments 70 I tem 1C. Cybersecurity 70 Item 2.

Properties

Properties 71 Item 3.

Legal Proceedings

Legal Proceedings 71 Item 4. Mine Safety Disclosures 71 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters , and Issuer Purchases of Equity Securities 72 Item 6. [Reserved] 73 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 73 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 89 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 90 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 90 Item 9A.

Controls and Procedures

Controls and Procedures 90 Item 9B. Other Information 91 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 91 PART III Item 10. Directors, Executive Officers and Corporate Governance 91 Item 11.

Executive Compensation

Executive Compensation 91 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 91 Item 13. Certain Relationships and Related Transactions, and Director Independence 91 Item 14. Principal Accountant Fees and Services 91 PART IV Item 15. Exhibits and Financial Statement Schedules 92 Item 16. Form 10-K Summary 96 SIGNATURE PAGE 97 "Altibodies ," "ARCALYST ," "Evkeeza ," "EYLEA ," "EYLEA HD," "Inmazeb ," "Libtayo ," "Praluent " (in the United States), "REGEN-COV ," "Regeneron ," "Regeneron Genetics Center ," "RGC ," " Veloci-Bi ," " VelociGene ," " VelociHum ," " VelociMab ," " VelocImmune ," " VelociMouse ," " VelociSuite ," " VelociT ," "Veopoz ," and "ZALTRAP " are trademarks of Regeneron Pharmaceuticals, Inc. Trademarks and trade names of other companies appearing in this report are, to the knowledge of Regeneron Pharmaceuticals, Inc., the property of their respective owners. This report refers to products of Regeneron Pharmaceuticals, Inc., its collaborators, and other parties. Consult the product label in each territory for specific information about such products. Table of Contents PART I

Business

Item 1. Business This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (where applicable, together with its subsidiaries, "Regeneron," "Company," "we," "us," and "our"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others: the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products") and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates") and research and clinical programs now underway or planned, including without limitation those discussed or referenced in this report, Regeneron's and its collaborators' earlier-stage programs, and the use of human genetics in Regeneron's research programs; the likelihood and timing of achieving any of our anticipated development milestones referenced in this report; safety issues resulting from the administration of Regeneron's Products and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; the likelihood, timing, and scope of possible regulatory approval and commercial launch of our late-stage product candidates and new indications for Regeneron's Products, including without limitation those discussed or referenced in this report; th

View Full Filing

View this 10-K filing on SEC EDGAR